GSK: Jemperli OKd for recurrent or advanced mismatch repair-deficient endometrial cancer

 

• Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4%
• 85.9% of patients had duration of response ≥12 months and 54.7% of patients had duration of response ≥24 months

https://www.biospace.com/article/releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/